Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Akt-Erk pathway
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Akt-Erk pathway
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 227, Issue 1, Pages 35-43
Publisher
Wiley
Online
2011-03-16
DOI
10.1002/jcp.22722
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer
- (2011) Yoshimichi Tanaka et al. CANCER BIOLOGY & THERAPY
- LTD4 induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells
- (2010) Toby McGovern et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Induction of interleukin 8 by American cockroach allergens from human airway epithelial cells via extracellular signal regulatory kinase and jun N-terminal kinase but not p38 mitogen-activated protein kinase
- (2010) Mey-Fann Lee et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Periplocin Inhibits Growth of Lung Cancer in vitro and in vivo by Blocking AKT/ERK Signaling Pathways
- (2010) Ze J. Lu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis
- (2010) Toshihiro Seike et al. CLINICAL & EXPERIMENTAL METASTASIS
- Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells
- (2010) Terry W. Moody et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway
- (2010) Yi-Chieh Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas
- (2010) Yoh Dobashi et al. HUMAN PATHOLOGY
- Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?
- (2010) Xiangdong Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development
- (2010) A. M. Gustafson et al. Science Translational Medicine
- Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy
- (2010) Yan Shi et al. TUMOR BIOLOGY
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells
- (2009) Jung-Chen Su et al. LIFE SCIENCES
- MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells
- (2008) Catherine Le Quément et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- Epidermal Growth Factor Receptor Signaling to Erk1/2 and STATs Control the Intensity of the Epithelial Inflammatory Responses to Rhinovirus Infection
- (2008) Kenneth Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Targeting RAS and PI3K in lung cancer
- (2008) Julian Downward NATURE MEDICINE
- Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt
- (2007) Juddi Yeh et al. LUNG CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started